PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 51.23

Change

0.00 (0.00)%

Market Cap

USD 3.27B

Volume

1.43M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-06 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+6.15 (+10.13%)

USD 23.46B
PODD Insulet Corporation

+17.68 (+7.16%)

USD 17.22B
MASI Masimo Corporation

+19.51 (+13.45%)

USD 7.80B
BRKR Bruker Corporation

+4.83 (+13.28%)

USD 5.53B
IRTC iRhythm Technologies Inc

+6.61 (+6.83%)

USD 3.28B
QDEL Quidel Corporation

+2.65 (+10.11%)

USD 2.42B
TMDX TransMedics Group Inc

+7.46 (+10.98%)

USD 2.27B
LIVN LivaNova PLC

+1.87 (+5.52%)

USD 1.95B
NVCR Novocure Ltd

+1.58 (+10.28%)

USD 1.81B
UFPT UFP Technologies Inc

+18.71 (+9.68%)

USD 1.62B

ETFs Containing PRCT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -36.38% 38% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.38% 38% F 24% F
Trailing 12 Months  
Capital Gain 8.91% 83% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.91% 83% B 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.30% 73% C 83% B
Dividend Return 32.30% 73% C 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.95% 56% F 34% F
Risk Adjusted Return 59.88% 96% N/A 83% B
Market Capitalization 3.27B 95% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector